KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Leases (2019 - 2025)

Jazz Pharmaceuticals has reported Leases over the past 14 years, most recently at $58.9 million for Q4 2025.

  • Quarterly results put Leases at $58.9 million for Q4 2025, up 9.89% from a year ago — trailing twelve months through Dec 2025 was $58.9 million (up 9.89% YoY), and the annual figure for FY2025 was $58.9 million, up 9.89%.
  • Leases for Q4 2025 was $58.9 million at Jazz Pharmaceuticals, down from $61.2 million in the prior quarter.
  • Over the last five years, Leases for JAZZ hit a ceiling of $125.7 million in Q1 2021 and a floor of $5.5 million in Q2 2021.
  • Median Leases over the past 5 years was $71.1 million (2023), compared with a mean of $69.5 million.
  • Biggest five-year swings in Leases: plummeted 95.88% in 2021 and later skyrocketed 1328.71% in 2022.
  • Jazz Pharmaceuticals' Leases stood at $86.6 million in 2021, then decreased by 15.31% to $73.3 million in 2022, then dropped by 10.89% to $65.3 million in 2023, then fell by 18.0% to $53.6 million in 2024, then rose by 9.89% to $58.9 million in 2025.
  • The last three reported values for Leases were $58.9 million (Q4 2025), $61.2 million (Q3 2025), and $63.1 million (Q2 2025) per Business Quant data.